* India ready for vaccines needing 2 to 8 degrees Celsius storage
* AstraZeneca, Bharat Biotech, RDIF's Sputnik V among frontrunners
* Pfizer , Moderna unlikely to be able to supply India with volumes until H2 2021
By Neha Arora and Sanjeev Miglani
NEW DELHI, Dec 11 (Reuters) - India will deploy its vast election machinery to deliver 600 million doses of COVID-19 vaccines to the most vulnerable people in the next six to eight months through conventional cold chain systems, the expert leading the initiative said on Friday.
The government has lined up cold storage facilities with temperatures between 2 to 8 degrees Celsius (36 to 48°F), said V.K. Paul, who heads the group of experts on vaccine administration for COVID-19 that advises India's Prime Minister Narendra Modi.
Paul said these preparations meet the requirements of what he said were the four emerging candidates in the race for India's vaccine.
"The four that I can see, including Serum, Bharat, Zydus, and Sputnik need normal cold chain. I see no problem for these vaccines," he told Reuters in an interview.
Serum Institute of India, the world's largest vaccine maker, is already mass producing and stockpiling AstraZeneca's AZN.L Covishield shot, while Indian biotech players Bharat Biotech and Zydus Cadila are developing their own vaccine candidates.
And last month, Indian pharmaceutical player Hetero inked a deal with Russia's RDIF to manufacture over 100 million doses of the Russian Sputnik V COVID-19 vaccine per year in India.
The government expects the first approvals "very soon" from the independent drug regulator for emergency use, he said.
"I am hoping at the earliest because we are ready."
The government, however, was yet to have formal talks on pricing and had no firm purchase orders, he said.
"The Indian companies know the government will give a fair and reasonable price."
SUPPLIES AND STORAGE
At present, Indian regulators are considering three vaccines for emergency use authorisation, including those from Pfizer Inc (NYSE: PFE ) PFE.N , AstraZeneca and Bharat Biotech. Pfizer's limited stockpiles and its extreme storage condition requirements at minus 70 degrees Celsius or below, would likely limit its use in India, which lacks such infrastructure.
"In a theoretical scenario, where there is no vaccine with conventional cold chain requirement, minus 70 degrees Celsius capacities will have to be created, and we will do so," Paul said.
Paul said the government is also in talks with Moderna MRNA.O , which also has requirements for ultra-cold storage.
India does not anticipate supplies from either Pfizer or Moderna until the second half of next year, said Paul.
"We would like to work with them (Moderna) to make that vaccine available in India, and (ensure) that vaccine is also manufactured in India - for us and for other countries. This is the call we have given to Pfizer also and we are in touch with them as well."
Paul said India may still consider granting Pfizer emergency use authorisation, despite it not having conducted safety and immune response trials in India, but said that decision would be taken by the drugs regulator.
"As of now, it is a norm or standard operating procedure that any vaccine marketed in India should have human study results from the Indian subjects," he said.
India has the world's second highest caseload of coronavirus behind the United States, but its death rate has been far lower.
Still, Paul said the immediate task was to protect lives and the government had prepared a plan to administer vaccines to 300 million people - or 600 million doses at two jabs each - in the first part of the programme.
This would be made up of 260 million people above the age of 50, an estimated 10 million below the age of 50 with serious co-morbidities and 30 million frontline workers, who have borne the brunt of infections.
"The way it looks as of now, optimistically, it appears possible to cover the above population of 300 million in six to eight months' time."
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.
Can any one tell me exactly when?Like 0